Breast Cancer-Targets and Therapy
Scope & Guideline
Bridging science and practice in breast cancer treatment.
Introduction
Aims and Scopes
- Targeted Therapies and Drug Development:
The journal publishes articles on the development and application of targeted therapies, including antibody-drug conjugates, immunotherapies, and small molecule inhibitors, aimed at specific breast cancer subtypes such as HER2-positive and triple-negative breast cancer. - Biomarkers and Prognostic Indicators:
Research focusing on identifying and validating biomarkers for breast cancer diagnosis, prognosis, and treatment response is a core area. This includes studies on circulating tumor DNA, microRNAs, and other molecular markers that can aid in personalized treatment approaches. - Radiotherapy Innovations:
The journal highlights advances in radiotherapy techniques, including hypofractionation and the use of novel dosimetric approaches to reduce toxicity and improve outcomes for breast cancer patients. - Clinical Guidelines and Practice:
Articles that discuss clinical guidelines, treatment protocols, and real-world evidence in the management of breast cancer are frequently featured, aiming to bridge the gap between research findings and clinical practice. - Epidemiological Studies and Risk Factors:
The journal also covers epidemiological research that identifies risk factors, lifestyle influences, and socio-economic determinants associated with breast cancer incidence and outcomes. - Patient-Centric Research:
There is a commitment to exploring patient perspectives, quality of life, and psychosocial aspects of breast cancer treatment, ensuring that research translates to tangible benefits for patients.
Trending and Emerging
- Liquid Biopsies and Non-Invasive Diagnostics:
The emergence of research on liquid biopsies, particularly the use of plasma exosomes and circulating tumor DNA, signifies a growing interest in non-invasive diagnostics that can monitor disease progression and treatment response. - Immunotherapy Advances:
There is a notable increase in studies exploring immunotherapy, including novel checkpoint inhibitors and vaccine strategies, which are becoming central to the treatment landscape for various breast cancer subtypes. - Precision Medicine:
Research focusing on precision medicine approaches, including genetic profiling and individualized treatment plans based on tumor characteristics, is gaining traction, reflecting a shift towards tailored therapies. - Nanotechnology in Treatment Delivery:
The application of nanotechnology for drug delivery systems and targeted therapies is an emerging theme, showcasing innovative methods to enhance the efficacy and reduce side effects of breast cancer treatments. - Role of the Tumor Microenvironment:
There is an increasing emphasis on understanding the tumor microenvironment and its role in breast cancer progression and therapy resistance, which is critical for developing effective treatment strategies.
Declining or Waning
- Traditional Chemotherapy Approaches:
There seems to be a waning emphasis on traditional chemotherapy regimens in favor of targeted and immunotherapeutic strategies, reflecting a broader trend towards personalized medicine. - Use of Traditional Chinese Medicine:
While previously a niche area of interest, the volume of research related to traditional Chinese medicine in breast cancer treatment appears to be decreasing, as more focus shifts towards evidence-based pharmacological therapies. - Basic Science Studies:
There has been a noticeable reduction in purely basic science studies that do not directly translate to clinical applications, as the journal increasingly favors translational research that impacts patient care.
Similar Journals
CANCER RESEARCH
Advancing the frontiers of oncology research.Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.
Journal of Cancer Metastasis and Treatment
Exploring breakthroughs in metastasis and therapy.Journal of Cancer Metastasis and Treatment, published by OAE PUBLISHING INC, stands as a vital resource in the field of oncology, focusing on advancements and research pertaining to cancer metastasis and treatment methodologies. With an ISSN of 2394-4722 and an E-ISSN of 2454-2857, this journal aims to serve as a comprehensive platform for sharing innovative research, critical analyses, and novel findings from 2019 through 2024. As indexed in Scopus, it holds a notable Q3 ranking within its category, positioned at 240/404 and within the 40th percentile, thus reflecting its growing significance in the scientific community. Though currently not open access, the journal aspires to improve accessibility to pivotal oncology research, making it an essential tool for researchers, clinicians, and students keen on unraveling the complexities of cancer treatment and metastasis. Its commitment to promoting high-quality studies plays a crucial role in the ongoing quest to enhance patient care and outcomes in cancer treatment.
PATHOLOGY & ONCOLOGY RESEARCH
Exploring the Nexus of Disease and TreatmentPATHOLOGY & ONCOLOGY RESEARCH is a prominent international journal published by FRONTIERS MEDIA SA, dedicated to advancing the fields of pathology and oncology. Operating from the Netherlands, with a distinguished address in Switzerland, this journal plays a crucial role in disseminating significant research findings and insights from 1995 to 2024. With an ISSN of 1219-4956 and E-ISSN of 1532-2807, it is indexed in well-respected databases, facilitating access to a global audience of researchers and practitioners. Notably, the journal ranks in the Q3 category for Cancer Research (2023), while being recognized in the Q2 categories for both Medicine (Miscellaneous), Oncology, and Pathology and Forensic Medicine, reflecting its authoritative status in these vital disciplines. Scopus rankings further highlight its influence, with notable percentiles across various fields. Although it follows a subscription model, the journal remains committed to publishing high-quality, peer-reviewed research that bridges conceptual gaps and encourages further exploration in oncology and diagnostic pathology, making it an indispensable resource for academics and professionals engaged in these critical areas of medicine.
Oncologie
Pioneering insights in the fight against cancer.Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.
Nature Reviews Clinical Oncology
Pioneering Insights for Tomorrow's TreatmentsNature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.
Breast Care
Innovating Solutions for Tomorrow's Breast Care ChallengesBreast Care is a prominent academic journal published by KARGER, focusing on the dynamic fields of oncology and surgery. With an ISSN of 1661-3791 and an E-ISSN of 1661-3805, this peer-reviewed journal has established itself as an essential resource for researchers, clinicians, and students dedicated to advancing breast health. Based in Switzerland, it benefits from a strong academic reputation, evident in its impressive Scopus rankings—placing it in the 79th percentile in Surgery (Rank #115/551) and the 53rd percentile in Oncology (Rank #188/404). The journal is recognized for its rigorous exploration of current trends, innovations, and challenges in breast care, encompassing a wide scope from surgical techniques to oncological therapies. With a Q2 ranking in Oncology and a notable Q1 ranking in Surgery as of 2023, Breast Care not only contributes to the advancement of medical knowledge but also fosters interdisciplinary collaboration among healthcare professionals worldwide.
ANTICANCER RESEARCH
Connecting Knowledge to Combat CancerANTICANCER RESEARCH, published by the International Institute of Anticancer Research, stands at the forefront of cancer-related scholarly communication. With ISSN 0250-7005 and E-ISSN 1791-7530, this esteemed journal has been serving the global research community since 1981, showcasing innovative research aimed at combating cancer through various therapeutic approaches and scientific inquiry. Based in Greece, the journal aims to disseminate vital findings in the fields of Cancer Research, Medicine, and Oncology, reflecting its notable categorization in the Q3 and Q2 quartiles as of 2023. Despite its rigorous peer-review process and the absence of open access, ANTICANCER RESEARCH remains a vital publication for researchers, clinicians, and students eager to stay updated on the evolving landscape of anticancer strategies. As it converges to its milestone year of 2024, the journal continues to enrich the discourse around cancer treatment and prevention, affirming its position as an essential resource for those dedicated to advancing knowledge in anticancer therapies.
Molecular and Clinical Oncology
Transforming insights into impactful oncology practices.Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.
ONCOLOGY
Elevating the standards of oncology research and practice.ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.
Oncology in Clinical Practice
Elevating Patient Outcomes Through Innovative ResearchOncology in Clinical Practice is a vital resource in the field of oncology, published by VIA MEDICA in Poland. This peer-reviewed journal, with ISSN 2450-1654 and E-ISSN 2450-6478, aims to bridge the gap between clinical practice and cancer research, providing a platform for the dissemination of original research, reviews, and case studies. Since its inception in 2019, the journal has featured significant contributions to the understanding of cancer treatment and patient care, although it currently holds a Q4 ranking in Oncology with a Scopus rank of #313/404 and a 22nd percentile in the Medicine _ Oncology category. Though it is not an open-access journal, its content is invaluable for oncologists, researchers, and students, offering critical insights and advancements in clinical approaches to cancer management. With a commitment to enhancing patient outcomes through clinical evidence, Oncology in Clinical Practice serves as an essential reference for those dedicated to the fight against cancer.